TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 900nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 1.90E+3nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 2.60E+3nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 6.50E+3nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 6.50E+3nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 7.50E+3nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 2.70E+4nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 3.70E+4nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src/SH2 domain-containing adapter protein B(Homo sapiens (Human))
Ariad Pharmaceuticals
Ariad Pharmaceuticals
Affinity DataIC50: 3.35E+5nMAssay Description:Compounds were tested for binding to Src SH2 using a fluorescence polarization binding assay according to methods previously described. IC50 values ...More data for this Ligand-Target Pair